Age-Driven Genetic and Epigenetic Heterogeneity in B-ALL
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26188774 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yoana Veselinova und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Epigenetics, Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Spain. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Genetic Heterogeneity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche José Carreras Leukämie Stiftung, Instituto de Salud Carlos III (ISCIII), European Union (ESF+).
Abstract (Originalsprache)
B-cell acute lymphoblastic leukemia (B-ALL) remains a major clinical challenge in hematologic oncology, characterized by a continuous evolution of molecular drivers that shape its heterogeneity across the age spectrum. Pediatric B-ALL is generally associated with high cure rates, while adult forms of the disease are often more aggressive and less responsive to treatment. This review examines the age-specific genetic and epigenetic landscapes that contribute to this disparity, revealing how the nature and timing of molecular alterations point to fundamentally different leukemogenic processes. Favorable genetic aberrations, such as ETV6::RUNX1 and hyperdiploidy, are predominant in children, whereas adults more frequently present with high-risk features, including BCR::ABL1 fusions and IKZF1 deletions. Epigenetic distinctions are similarly age-dependent, involving divergent patterns of DNA methylation, histone modifications, and non-coding RNA expression. For example, pediatric B-ALL frequently harbors mutations in epigenetic regulators like SETD2 and CREBBP, while adult B-ALL is more commonly affected by alterations in TET2 and IDH1/2. These molecular differences are not only prognostic but also mechanistic, reflecting distinct developmental trajectories and vulnerabilities. Understanding these age-driven transitions is essential for improving risk stratification and developing precision therapies tailored to the unique biology of B-ALL across the lifespan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Epigenetics, Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Spain.
- Institució Catalana de Recerca i Estudis Avançats (ICREA) and Universitat Pompeu Fabra, 08010 Barcelona, Spain.
- Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), 08036 Barcelona, Spain.
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029 Madrid, Spain.
- Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, 08916 Badalona, Spain.
- Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY 11030, USA.
ORCID-Profile: Manel Esteller, Gerardo Ferrer
Förderung
- Deutsche José Carreras Leukämie Stiftung
- Instituto de Salud Carlos III (ISCIII)
- European Union (ESF+)
- CERCA Programme/Generalitat de Catalunya
- European Regional Development Fund, ‘A way to make Europe’ ERDF
- Departament de Recerca i Universitats/Generalitat de Catalunya
- European Union under THRIVE Grant Agreement
- Cellex Foundation
Zitieren
APA
Veselinova, Y., Esteller, M., & Ferrer, G. (2025). Age-Driven Genetic and Epigenetic Heterogeneity in B-ALL. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26188774
Vancouver
Veselinova Y, Esteller M, Ferrer G. Age-Driven Genetic and Epigenetic Heterogeneity in B-ALL. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26188774
BibTeX
@article{Veselinova2025,
author = {Veselinova, Yoana and Esteller, Manel and Ferrer, Gerardo},
title = {Age-Driven Genetic and Epigenetic Heterogeneity in B-ALL},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26188774}
}
EUVIMED